Selecting a Favorable KIR Donor in Unrelated HCT for AML

NACompletedINTERVENTIONAL
Enrollment

506

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
Acute Myelogenous Leukemia
Interventions
OTHER

KIR genotype

KIR genotype data from unrelated donor are collected

Trial Locations (19)

10021

New York Presbyterian Weill Cornell Medical Center, New York

14263

Roswell Park Cancer Institute, Buffalo

19104

University of Pennsylvania, Philadelphia

30322

Emory University, Atlanta

43210

Ohio State University Comprehensive Cancer Center, Columbus

44195

Cleveland Clinic, Cleveland

46202

Indiana University Simon Cancer Center, Indianapolis

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

55905

Mayo Clinic Cancer Center, Rochester

60637

University of Chicago Medical Center Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

66160

Kansas University Cancer Center, Kansas City

75246

Baylor Sammons Cancer Center, Dallas

77030

M.D. Anderson Cancer Center, Houston

78229

Methodist Healthcare System of San Antonio, San Antonio

80218

Colorado Blood Cancer Institute, Denver

85259

Mayo Clinic - Scottsdale, Scottsdale

98109

Fred Hutchinson Cancer Research Center, Seattle

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT01288222 - Selecting a Favorable KIR Donor in Unrelated HCT for AML | Biotech Hunter | Biotech Hunter